• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,210.77
  • 0.75 %
  • $61.50
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
App Store Download on the App Store Google Play GET IT ON Google Play

Get The App

App Store Download on the App Store Google Play GET IT ON Google Play
Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

Currency in USD Disclaimer

$122.91

-$1.48

(-1.19%)

Day's range
$122.43
Day's range
$124.63
50-day range
$114.53
Day's range
$155.53
  • Country: DK
  • ISIN: US04351P1012
52 wk range
$90.13
Day's range
$161
  • CEO: Mr. Jan Moller Mikkelsen
  • Website: Visit Site


We are preparing, please wait

1 Hour 1 Day 1 Week 1 Year Advanced Chart
Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.02
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (ASND)
  • Company Ascendis Pharma A/S
  • Price $122.91
  • Changes Percentage (-1.19%)
  • Change -$1.48
  • Day Low $122.43
  • Day High $124.63
  • Year High $161.00

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/05/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $196.00
  • High Stock Price Target $289.00
  • Low Stock Price Target $136.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$9.67
  • Trailing P/E Ratio -14.19
  • Forward P/E Ratio -14.19
  • P/E Growth -14.19
  • Net Income $-481,447,000

Income Statement

Quarterly

Annual

Latest News of ASND

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

View ALL
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Ascendis Pharma A/S Frequently Asked Questions

  • What is the Ascendis Pharma A/S stock price today?

    Today's price of Ascendis Pharma A/S is $122.91 — it has decreased by -1.19% in the past 24 hours. Watch Ascendis Pharma A/S stock price performance more closely on the chart.

  • Does Ascendis Pharma A/S release reports?

    Yes, you can track Ascendis Pharma A/S's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Ascendis Pharma A/S stock forecast?

    Watch the Ascendis Pharma A/S chart and read a more detailed Ascendis Pharma A/S stock forecast to see what analysts suggest you do with its shares.

  • What is Ascendis Pharma A/S stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Ascendis Pharma A/S stock ticker.

  • How to buy Ascendis Pharma A/S stocks?

    Like other stocks, ASND shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Ascendis Pharma A/S's EBITDA?

    Ascendis Pharma A/S measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Ascendis Pharma A/S’s financial statements.

  • What is the Ascendis Pharma A/S's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -1.8050787723, which equates to approximately -180.51%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Ascendis Pharma A/S stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Ascendis Pharma A/S's financials relevant news, and technical analysis. Ascendis Pharma A/S's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Ascendis Pharma A/S stock currently indicates a “sell” signal. For more insights, review Ascendis Pharma A/S’s technical analysis.

  • A revenue figure for Ascendis Pharma A/S for its last quarter?

    Ascendis Pharma A/S published it's last quarterly revenues at $57.83 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In

or
download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Sign Up With Email Address
or
google app download Continue with Google ios app download Continue with Apple

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.